James R. Berenson
- Hematology top 0.05%
- Multiple Myeloma Research and Treatments 262
- Oncology top 0.1%
- Peptidase Inhibition and Analysis 66
- Bone health and treatments 62
- Cancer Treatment and Pharmacology 39
- Orthopedics and Sports Medicine top 0.5%
- Molecular Biology top 1%
- Protein Degradation and Inhibitors 91
- Immunology top 1%
-
- Radiopharmaceutical Chemistry and Applications 37
- Monoclonal and Polyclonal Antibodies Research 37
-
- Chronic Lymphocytic Leukemia Research 36
- Co-authors
- Robert VescioAllan LiptonAlan LichtensteinRegina A. SwiftBart BarlogieKenneth C. AndersonSundar JagannathPaul G. Richardson
- Journals
- Science (1 paper)New England Journal of Medicine (1 paper)Proceedings of the National Academy of Sciences (2 papers)
- Partner nations
- United StatesCanadaGreece
In The Last Decade
James R. Berenson
382 papers receiving 13.6k citations
Hit Papers
Peers
Comparison fields: 5 of 129
- Hematology 6.7k
- Oncology 7.9k
- Orthopedics and Sports Medicine 1.2k
- Molecular Biology 5.9k
- Immunology 1.7k
Countries citing papers authored by James R. Berenson
This map shows the geographic impact of James R. Berenson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James R. Berenson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James R. Berenson more than expected).
Fields of papers citing papers by James R. Berenson
This network shows the impact of papers produced by James R. Berenson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James R. Berenson. The network helps show where James R. Berenson may publish in the future.
Co-authorship network
The 25 scholars most cited alongside James R. Berenson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 5 | |
| 3 | 2023 | 1 | |
| 4 | 2022 | 10 | |
| 5 | 2021 | 33 | |
| 6 | 2020 | 25 | |
| 7 | 2020 | 2 | |
| 8 | 2019 | 13 | |
| 9 | 2017 | 18 | |
| 10 | 2017 | 6 | |
| 11 | 2017 | 1 | |
| 12 | 2017 | 1 | |
| 13 | 2014 | 2 | |
| 14 | 2010 | 8 | |
| 15 | 2009 | 78 | |
| 16 | ATN-224, an orally available small molecule inhibitor of SOD1, inhibits multiple signaling pathways associated with myeloma progression and has antitumor activity in a murine model of refractory myeloma growth | 2006 | 5 |
| 17 | 2004 | 7 | |
| 18 | 2002 | 51 | |
| 19 | 2002 | 25 | |
| 20 | Pamidronate in the treatment of osteolytic bone lesions in multiple myeloma patients--the American experience. | 1996 | 9 |
About James R. Berenson
James R. Berenson is a scholar working on Hematology, Oncology and Genetics, having authored 389 papers that have together received 14.0k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (262 papers), Protein Degradation and Inhibitors (91 papers), Peptidase Inhibition and Analysis (66 papers), Bone health and treatments (62 papers), Cancer Treatment and Pharmacology (39 papers), Radiopharmaceutical Chemistry and Applications (37 papers), Monoclonal and Polyclonal Antibodies Research (37 papers) and Chronic Lymphocytic Leukemia Research (36 papers). The work is most often cited by research in Hematology (6.7k citations), Oncology (7.9k citations) and Orthopedics and Sports Medicine (1.2k citations). James R. Berenson has collaborated with scholars based in United States, Canada and Greece. Frequent co-authors include Robert Vescio, Allan Lipton, Alan Lichtenstein, Regina A. Swift, Bart Barlogie, Kenneth C. Anderson, Sundar Jagannath, Paul G. Richardson, John J. Seaman and David Irwin. Their work appears in journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.